Management and outcome of hepatocellular adenoma with massive bleeding at presentation.

Autor:	Klompenhouwer AJ; Anne J Klompenhouwer, Jan NM Ijzermans, Department of Surgery, Erasmus MC, 3000 CA Rotterdam, the Netherlands., de Man RA; Anne J Klompenhouwer, Jan NM Ijzermans, Department of Surgery, Erasmus MC, 3000 CA Rotterdam, the Netherlands., Thomeer MG; Anne J Klompenhouwer, Jan NM Ijzermans, Department of Surgery, Erasmus MC, 3000 CA Rotterdam, the Netherlands., Ijzermans JN; Anne J Klompenhouwer, Jan NM Ijzermans, Department of Surgery, Erasmus MC, 3000 CA Rotterdam, the Netherlands.
Jazyk:	angličtina
Zdroj:	World journal of gastroenterology [World J Gastroenterol] 2017 Jul 07; Vol. 23 (25), pp. 4579-4586.
DOI:	10.3748/wjg.v23.i25.4579
Abstrakt:	Aim: To evaluate outcome of acute management and risk of rebleeding in patients with massive hemorrhage due to hepatocellular adenoma (HCA). Methods: This retrospective cohort study included all consecutive patients who presented to our hospital with massive hemorrhage (grade II or III) due to ruptured HCA and were admitted for observation and/or intervention between 1999-2016. The diagnosis of HCA was based on radiological findings from contrast-enhanced magnetic resonance imaging (MRI) or pathological findings from biopsy or resection of the HCA. Hemorrhage was diagnosed based on findings from computed tomography or MRI. Medical records were reviewed for demographic features, clinical presentation, tumor features, initial and subsequent management, short- and long-term complications and patient and lesion follow-up. Results: All patients were female ( n = 23). Treatment in the acute phase consisted of embolization ( n = 9, 39.1%), conservative therapy ( n = 13, 56.5%), and other intervention ( n = 1, 4.3%). Median hemoglobin level decreased significantly more on days 0-3 in the intervention group than in the patients initially treated conservatively (0.9 mmol/L vs 2.4 mmol/L respectively, P = 0.006). In total, 4 patients suffered severe short-term complications, which included hypovolemic shock, acute liver failure and abscess formation. After a median follow-up of 36 mo, tumor regression in non-surgically treated patients occurred with a median reduction of 76 mm down to 25 mm. Four patients underwent secondary (elective) treatment ( i.e ., tumor resection) to address HCA size of > 5 cm and/or desire for future pregnancy. One case of rebleeding was documented (4.3%). None of the patients experienced long-term complication (mean follow-up time: 36 mo). Conclusion: With a 4.3% risk of rebleeding, secondary (elective) treatment of HCA after massive hemorrhage may only be considered in patients with persistent HCA > 5 cm. Competing Interests: Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu